Remove tag evidence
article thumbnail

Pioneering the Path Pre- and Post-Launch Strategies

PM360

Driving an Integrated Evidence Strategy Evidence-based decision-making and differentiation are of paramount importance for HCPs who are flooded with therapy options or are circumspect to adopt a new therapy. An honest understanding of Medical Affairs situations and needs will be essential to ensure data-driven decision-making.

Medical 52
article thumbnail

These seven ADC makers are developing therapies that show promise for hard-to-treat cancers

Clarivate

To better understand the scientific status quo and identify some promising innovators, Clarivate analysts reviewed data on deal valuations, clinical trials and market approvals in the space to identify seven ADC Companies to Watch , including: Adcendo ApS , a company based in Denmark whose lead program targets the uPARAP receptor, which is overexpressed (..)

Pharma 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

The FDA and Aduhelm: WTF?

World of DTC Marketing

Not to mention the $56,000 annual price tag. While it’s not clear that Aduhelm actually slows down Alzheimer’s, there was “convincing evidence” that it had a “robust” effect on amyloid plaques. Aduhelm joins a group of drugs that potentially leave patients worse off and much poorer for it.

FDA 218
article thumbnail

J&J builds case for antidepressant Spravato with head-to-head trial

pharmaphorum

Yesterday, the drugmaker added to the evidence behind Spravato – an intranasal formulation of esketamine – with the release of top-line data from a head-to-head study with a long-acting formulation of the antipsychotic quetiapine, which is also used to treat TRD.

Sales 52
article thumbnail

Can gene therapies for haemophilia defend their high price tags?

Pharmaceutical Technology

On November 2, the Institute for Clinical and Economic Review (ICER) released its updated evidence aimed at measuring the clinical effectiveness and cost of the two haemophilia gene therapies. million price tag. The post Can gene therapies for haemophilia defend their high price tags? million ($1.8 million at the time).

Safety 111
article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Still, comparing the two therapies remains difficult, with ICER rating the evidence as insufficient.

article thumbnail

How to Optimize Content for SEO to Rank Higher

Healthcare Success

This process can apply to everything from building a better, clean site architecture to updating web pages with optimized title tags, meta description tags, headings, and body content that reflects what people are searching for. As with all aspects of SEO, content shouldn’t be “optimized” just for the search engine algorithms.